Parkinson’s disease is a progressive movement disorder caused when
dopamine producing nerve cells function irregularly. Dopamine regulates
movement by sending signals to the brain and facilitates the smooth
functioning of muscles. Some of the major symptoms of Parkinson’s
disease include hand, arms or leg tremors, slow movement, problems
associated with balancing and walking and stiff muscles. The fact that
this disease is progressive in nature debilitates the patient’s
condition and the later symptoms of Parkinson’s include trouble
swallowing, constipation, fixed or blank expressions, dementia and
speech disabilities.
The growing global prevalence of Parkinson’s disease is the primary
growth driver of the global Parkinson’s disease therapeutics market
owing to the fact the an increase in the prevalence of this disease
directly widens the target population base for market players. According
to the estimates of the WHO, the global prevalence of Parkinson’s
disease was valued at over 10 million in 2012. Moreover, estimates
suggest that almost one million Americans are currently living with this
disease.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/parkinson-disease-therapeutics-industry
Incidence rates of Parkinson’s disease increase with aging and the
fact that the percentage of the world’s population above the age of 65
years will increase from 7% in 2000 to 16% in 2050 will serve this
market as a driver. The introduction of alternative therapeutic options
such as deep brain stimulation devices and the presence of high unmet
medical needs in emerging markets such as India, China and Brazil will
also have a positive impact on the market.
The overall therapeutic market for Parkinson’s disease can be
segmented into four major categories namely drug therapy, deep brain
stimulation devices, ablative neurosurgery and others. The drug therapy
segment currently dominates the market in terms of revenue share. Patent
expiration of key drugs such as Novartis or Orion Pharma’s
Comtan/Stalevo/Comtess and Teva Pharmaceuticals or Lundbeck’s
Azilect/Agilect will have a negative impact on this product segment’s
growth.
However, the presence of a strong pipeline is expected to offset the
revenue loss due to patent expirations. Some of the major products
currently in pipeline include Impax Laboratories/GlaxoSmithKline’s
IPX-066, Kyowa Hakko Kirin’s adenosine A2A receptor antagonist
istradefylline and Merck Serono/EMD Serono/Newron Pharmaceuticals’ MAO-B
inhibitor safinamide.
This research report provides comprehensive market statistics and
forecast for key segments, and provides complete industry landscape
including drivers, restraints, regulatory scenario, technology trends
and future opportunities. The report also provides detailed competitive
landscape with company market share analysis and in-depth profiles of
key market participants. Key regional markets analyzed and reported in
this study include:
- North America
- Europe
- Asia Pacific
- RoW
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/25
Critical elements of the report include:
- Industry dynamics
- Market challenges and opportunities
- Technology & regulatory trends
- Market estimate and forecast
- Regional trends
- Competitive trends
Why should you buy this report?
- This report provides comprehensive analysis of the market including Porter’s and SWOT analysis
- Complete identification and analysis of key industry dynamics including drivers, restraints, raw material trends and buyer behavior
- The study provides technology landscape and regulatory trends for building strategy
- Global and regional market estimates and forecast on volume and revenue basis for multiple market segments
- Detailed competitive landscape of the market, with profiles of key companies
Browse Full Report @ http://www.hexaresearch.com/research-report/parkinson-disease-therapeutics-industry
About Us:
Hexa Research is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit our Blog: http://hexaresearchinc.blogspot.com/
No comments:
Post a Comment